Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial

The Lancet Gastroenterology and Hepatology

Volumn 3, Issue 1, 2018, Pages 17-24

  Johnsen, Peter Holger ^a,c   Hilpüsch, Frank ^b,c   Cavanagh, Jorunn Pauline ^a,c   Leikanger, Ingrid Sande ^a   Kolstad, Caroline ^c   Valle, Per Christian ^a   Goll, Rasmus ^a,c  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b Sjøkanten Legesenter   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CALGRANULIN; CREATININE; CYANOCOBALAMIN; FERRITIN; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; LOPERAMIDE; PANCREATIC ELASTASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SODIUM; THYROTROPIN; THYROXINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CAMPYLOBACTER; CECUM; COLONOSCOPY; CONTROLLED STUDY; DIARRHEA; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ERYTHROCYTE SEDIMENTATION RATE; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTENTION TO TREAT ANALYSIS; IRRITABLE COLON; NAUSEA; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SALMONELLA; SHIGELLA; VERTIGO; YERSINIA; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROOF OF CONCEPT;

ABDOMINAL PAIN; ADULT; DOUBLE-BLIND METHOD; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; NAUSEA; PROOF OF CONCEPT STUDY; VERTIGO;

EID: 85037611386     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30338-2     Document Type: Article

References (30)

1. Enck, P, Aziz, Q, Barbara, G, et al. Irritable bowel syndrome. Nat Rev Dis Prim, 2, 2016, 16014.
2. Inadomi, JM, Fennerty, MB, Bjorkman, D, Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 18 (2003), 671–682.
3. Gralnek, IM, Hays, RD, Kilbourne, A, Naliboff, B, Mayer, EA, The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119 (2000), 654–660.
4. Gibson, PR, Shepherd, SJ, Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 25 (2010), 252–258.
5. Berg, LK, Fagerli, E, Martinussen, M, Myhre, A-O, Florholmen, J, Goll, R, Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test. Scand J Gastroenterol 48 (2013), 936–943.
6. Bennet, SMP, Ohman, L, Simren, M, Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver 9 (2015), 318–331.
7. Ahmad, OF, Akbar, A, Microbiome, antibiotics and irritable bowel syndrome. Br Med Bull 120 (2016), 91–99.
8. Lee, WJ, Lattimer, LDN, Stephen, S, Borum, ML, Doman, DB, Fecal microbiota transplantation: a review of emerging indications beyond relapsing Clostridium difficile toxin colitis. Gastroenterol Hepatol (N Y) 11 (2015), 24–32.
9. Simrén, M, Barbara, G, Flint, HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62 (2013), 159–176.
10. Kelly, CR, Kahn, S, Kashyap, P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149 (2015), 223–237.
11. Chang, L, From Rome to Los Angeles–the Rome III criteria for the functional GI disorders. Gastroenterology 130 (2006), 1480–1491.
12. Francis, CY, Morris, J, Whorwell, PJ, The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11 (1997), 395–402.
13. Spiller, R, Aziz, Q, Creed, F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56 (2007), 1770–1798.
14. Miller, LE, Study design considerations for irritable bowel syndrome clinical trials. Ann Gastroenterol 27 (2014), 338–345.
15. Norwegian Food Safety Authority. Norwegian food composition table. http://www.matvaretabellen.no, 2016 (accessed Aug 27, 2016).
16. Biesiekierski, JR, Rosella, O, Rose, R, et al. Quantification of fructans, galacto-oligosacharides and other short-chain carbohydrates in processed grains and cereals. J Hum Nutr Diet 24 (2011), 154–176.
17. Muir, JG, Rose, R, Rosella, O, et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). J Agric Food Chem 57 (2009), 554–565.
18. Whelan, K, Abrahmsohn, O, David, GJP, et al. Fructan content of commonly consumed wheat, rye and gluten-free breads. Int J Food Sci Nutr 62 (2011), 498–503.
19. Triantafyllou, K, Problems and challenges in the design of irritable bowel syndrome clinical trials. Focusing on the future with the experience from the past. Ann Gastroenterol 15 (2002), 263–270.
20. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry irritable bowel syndrome: clinical evaluation of drugs for treatment. https://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf, 2012 (accessed June 12, 2017).
21. Committee for Medicinal Products for Human use. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500173457.pdf, 2014 (accessed June 12, 2017).
22. Hilpüsch, F, Johnsen, PH, Goll, R, Valle, PC, Sørbye, SW, Abelsen, B, Microscopic colitis: a missed diagnosis among patients with moderate to severe irritable bowel syndrome. Scand J Gastroenterol 52 (2016), 173–177.
23. Staudacher, HM, Irving, PM, Lomer, MCE, Whelan, K, Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 11 (2014), 256–266.
24. Jalanka, J, Mattila, E, Jouhten, H, et al. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med, 14, 2016, 155.
25. Broecker, F, Klumpp, J, Schuppler, M, et al. Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation. Mol Case Stud, 2, 2016, a000448.
26. Lynch, S V, Pedersen, O, The human intestinal microbiome in health and disease. N Engl J Med 375 (2016), 2369–2379.
27. van Nood, E, Vrieze, A, Nieuwdorp, M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
28. Whitehead, WE, Palsson, OS, Levy, RR, Feld, AD, Turner, M, Von Korff, M, Comorbidity in irritable bowel syndrome. Am J Gastroenterol 102 (2007), 2767–2776.
29. Whitehead, WE, Palsson, O, Jones, KR, Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. Gastroenterology 122 (2002), 1140–1156.
30. Grundmann, O, Yoon, SL, Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 25 (2010), 691–699.